Lack of robust predictive biomarkers, other than MGMT promoter methylation, makes temozolomide responsiveness in newly diagnosed glioblastoma (GBM) patients difficult to predict. However, we identified patients with long-term survival (≥35 months) within a group of newly diagnosed GBM patients treated with standard or metronomic adjuvant temozolomide schedules. We thus investigated possible molecular profiles associated with longer survival following temozolomide treatment.
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide / Cominelli, Manuela; Grisanti, Salvatore; Mazzoleni, Stefania; Branca, Caterina; Buttolo, Luciano; Furlan, Daniela; Liserre, Barbara; Bonetti, Maria Fausta; Medicina, Daniela; Pellegrini, Vilma; BUGLIONE DI MONALE E BASTIA, Michela; Liserre, Roberto; Pellegatta, Serena; Finocchiaro, Gaetano; Dalerba, Piero; Facchetti, Fabio; Pizzi, Marina; Galli, Rossella; Poliani, Pietro Luigi. - In: JOURNAL OF THE NATIONAL CANCER INSTITUTE. - ISSN 0027-8874. - 107:5(2015). [10.1093/jnci/djv041]
EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide
POLIANI, Pietro Luigi
2015-01-01
Abstract
Lack of robust predictive biomarkers, other than MGMT promoter methylation, makes temozolomide responsiveness in newly diagnosed glioblastoma (GBM) patients difficult to predict. However, we identified patients with long-term survival (≥35 months) within a group of newly diagnosed GBM patients treated with standard or metronomic adjuvant temozolomide schedules. We thus investigated possible molecular profiles associated with longer survival following temozolomide treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
